Skip to main content
HR 5739 115th Congress House Health Administrative law and regulatory procedures Administrative remedies Advisory bodies Civil actions and liability Congressional oversight Consumer affairs Department of Health and Human Services Drug safety, medical device, and laboratory regulation Evidence and witnesses Food and Drug Administration (FDA) Government studies and investigations Health care costs and insurance Health technology, devices, supplies Inflation and prices Intellectual property Manufacturing Medicaid Prescription drugs Sales and excise taxes

Prescription Drug and Medical Device Price Review Board Act of 2018

Introduced: May 9, 2018 Introduced by: DeLauro, Rosa L. Democratic · Connecticut See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 25, 2018
Referred to the Subcommittee on Health.
May 9, 2018
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 9, 2018
Introduced in House
 Plain-English summary Congressional Research Service

Prescription Drug and Medical Device Price Review Board Act of 2018

This bill establishes the Prescription Drug and Medical Device Price Review Board within the Food and Drug Administration. Each manufacturer of a prescription drug or medical device that is sold in the United States must submit to the board:

  • each type of prescription drug and medical device that it sells in the United States, or in a country that is a member of the Organization for Economic Co-operation and Development;
  • the price charged by the manufacturer for the drug or device; and
  • the costs of the manufacturer to produce them.

The board must establish a formula for determining whether the average manufacturer price of a prescription drug or medical device over an annual quarter is an excessive price. Manufacturers may not charge excessive prices. Individuals may petition the board to determine whether the price for a prescription drug or medical device is excessive.

The board may subject violators to reduced patent terms, civil penalties, and increased Medicaid rebates payable to states. The bill amends the Internal Revenue Code to impose a tax on the sale of prescription drugs or medical devices that have excessive prices.

The board must allow individuals to import from approved counties prescription drugs and devices that are comparable to prescription drugs and devices with excessive prices.

What's happening now May 25, 2018

Referred to the Subcommittee on Health.

 Committees of jurisdiction 4
 Cosponsors 2
All 2 Democratic 2